This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=98 http://www.lsis.com/goto/r98/rss 2012-02-05T11:11:02+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Recipients of extended-criteria donor (ECD) kidneys have poorer long-term outcomes compared to standard-criteria donor kidney recipients. We report 3-year outcomes from a randomized, phase III study in recipients of de novo ECD kidneys (n = 543) assigned (1:1:1) to either a more intensive (MI) or less intensive (LI) belatacept regimen, or cyclosporine. Three hundred twenty-three patients completed treatment by year 3. Patient survival with a functioning graft was comparable between groups (80% (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Effects of material and manufacturing process parameters on the efficiency of an aqueous active tablet film-coating process in a perforated pan coater were evaluated. Twenty-four batches representing various tablet core weights, sizes, and shapes were coated at the 350-500kg scale. The coating process efficiency, defined as the ratio of the amount of active deposited on tablet cores to the amount of active sprayed, ranged from 86 to 99%. Droplet size and the velocity of the coating spray were (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 NEW YORK-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR) for its tender offer for Inhibitex, Inc. (NASDAQ: INHX) has expired. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 PURPOSE: This study examined potential correlations between markers related to the insulin-like growth factor-1 receptor (IGF-1R) pathway and clinical benefit from the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in metastatic colorectal cancer (mCRC).EXPERIMENTAL DESIGN: Gene expression profiles for 70 pretreatment specimens from metastatic lesions of patients with chemorefractory mCRC receiving cetuximab monotherapy were analyzed using 74 predefined Gene-Chip (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 A leak test performed according to ASTM F2338-09 Standard Test Method for Nondestructive Detection of Leaks in Packages by Vacuum Decay Method was developed and validated for container-closure integrity verification of a lyophilized product in a parenteral vial package system. This nondestructive leak test method is intended for use in manufacturing as an in-process package integrity check, and for testing product stored on stability in lieu of sterility tests. Method development and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Background: The lack of adequate glycaemic control for patients with type 2 diabetes mellitus (T2DM), especially with existing second-line therapies, represents an unmet medical need. Of the newer therapies, the incretin-based medicines, such as saxagliptin, look promising to consolidate second-line pharmacotherapy. Objective: This study evaluates the long-term economic consequences of saxagliptin versus sulfonylurea (glipizide) as second-line therapy when used in combination with metformin (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 SAN DIEGO-(BUSINESS WIRE)- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) in San Diego. The Phase II study was completed in late 2011 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Hepatitis C virus (HCV) protease inhibitors combined with pegylated interferon alfa/ribavirin have demonstrated improved efficacy compared with pegylated interferon alpha/ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single (SAD) and multiple ascending dose (MAD) studies in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 An evaporative light scattering detection (ELSD) based high-performance liquid chromatography (HPLC) method is developed for the determination of polysorbate 80 (tween 80) in therapeutic protein formulations. The method is simple and overcomes the difficulties associated with specificity and sensitivity. The method is suitable for the quantitation of polysorbate 80 in the usual formulation range (0.01-0.1%) as well as in trace amounts ?13 µg/mL. The analysis is based on the removal of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Instrumented roll technology on Alexanderwerk() WP120 roller compactor was developed and utilized successfully for the measurement of normal stress on ribbon during the process. The effects of process parameters such as roll speed (4-12rpm), feed screw speed (19-53rpm), and hydraulic roll pressure (40-70bar) on normal stress and ribbon density were studied using placebo and active pre-blends. The placebo blend consisted of 1:1 ratio of microcrystalline cellulose PH102 and anhydrous lactose (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 We developed a method to completely regenerate the gold (Au) surface of 3-aminopropyltriethoxysilane (APTES)-functionalized Au-coated surface plasmon resonance (SPR) chip that had been used for human fetuin A (HFA) immunoassay. It involved treatment of the used SPR chip with freshly prepared piranha solution (concentrated H(2)SO(4)/30% H(2)O(2)=3:1, v/v) for 15min followed by extensive rinsing with ethanol and deionized water. The developed method enabled prolonged reuse of the regenerated SPR (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Many medicines, including several cholesterol-lowering agents (eg, lovastatin, simvastatin), antihypertensives (eg, diltiazem, nifedipine, verapamil), and antifungals (eg, ketoconazole) are metabolized by and/or inhibit the cytochrome P450 (CYP) 3A4 metabolic pathway. These types of medicines are commonly coprescribed to treat comorbidities in patients with type 2 diabetes mellitus (T2DM) and the potential for drug-drug interactions of these medicines with new medicines for T2DM must be (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=98 United States Patent: 8105804 |-| Title: Polynucleotides encoding novel PCSK9 variants |-| Inventors: Mintier; Gabriel A. (Hightstown, NJ), Chen; Jian (Princeton, NJ), Feder; John N. (Belle Mead, NJ), Miao; Bowman (Churchville, PA), Parker; Rex Arnold (Titusville, NJ) |-| Assignee: Bristol-Myers Squibb Company (Princeton, NJ) |-| The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=98 United States Patent: 8106046 |-| Title: Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-.kappa.B activity and use thereof |-| Inventors: Yang; Bingwei Vera (Belle Mead, NJ) |-| Assignee: Bristol-Myers Squibb Company (Princeton, NJ) |-| A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined herein. Also disclosed are (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Ternary blends consisting of efavirenz (a model drug compound), lactose monohydrate, and a polymeric binder were investigated to verify the "physical state theory" in which granulation occurs only when binders undergo transition from glassy state to rubbery solution state. Furthermore, it was found that the rheological properties of the binders can significantly affect the granulation process. The blends with binders of viscous flow [polyvinylpyrrolidone (PVP) K17, PVP K25, and PVP K29/32 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 INTRODUCTION: Coronary heart disease, stroke, and peripheral vascular disease are the most common causes of mortality in patients with type 2 diabetes mellitus (T2DM). The aim of these studies was to assess the potential for pharmacokinetic interaction between dapagliflozin, a sodium glucose co-transporter-2 inhibitor being developed for the treatment of T2DM, and four medications commonly prescribed in patients with T2DM and cardiovascular disease: simvastatin, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Amorphous forms of poorly soluble drugs are more frequently being incorporated into solid dispersions for administration and extensive research has led to a reasonable understanding of how these dispersions, although still kinetically unstable, improve stability relative to the pure amorphous form. There remains however a paucity of literature describing the effects on such solid dispersions of subsequent processing into solid dosage forms such as tablets. This paper addresses this area by (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 There are four tests - the likelihood ratio (LR) test, Wald's test, the score test and the exact test - commonly employed in genetic association studies. On comparison of the four tests, we found that Wald's test, popular in genome-wide screens due to its low computational demands, exhibited a paradoxical behaviour in that the test statistic decreased as the effect size of the variant increased, resulting in a loss of power. The LR test always achieved the most significant P-values, followed (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Apixaban (BMS-562247-01) is a compound being investigated as an anticoagulant. Apixaban molecule is developed in a joint venture by Pfizer and Bristol-Myers Squibb. Apixaban, a coagulation factor Xa inhibitor, approved in the E.U. in 2011 for the prevention of venous thromboembolic events in adult patients, who have undergone elective hip or knee replacement. The Apixaban based drug will be marketed under the brand name Eliquis and is expected to rack up annual sales of over $2.5 billion. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 The stability of a 1,2,4-oxadiazole derivative, BMS-708163, A, was studied in the cosolvent mixture of acetonitrile-water at various pH values, in the solid state and in the presence of various excipients. The objective of this study was to develop a deep understanding of the stability of compound A based on its degradation kinetics and mechanism to enable design of a robust drug product. A series of isotopically (13) C- and (15) N-labeled compounds were synthesized and their degradation was (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Aims: In order to test the anti-diabetic efficacy of ibipinabant, this new cannabinoid receptor 1 (CB1) antagonist was compared with food-restriction-induced weight loss, rosiglitazone (4 mg/kg) and rimonabant (3 and 10 mg/kg), using parameters of glycemic control in male ZDF rats. Materials and Methods: Body weight, food and water intake, fasted and nonfasted glucose and insulin, glucose tolerance, and glycosylated hemoglobin (HbA1c) were all assessed over the course of the 9 week study. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 NEW YORK-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) today announced solid financial results for the fourth quarter of 2011. This concludes a year in which the Company received important new product approvals for YERVOY and NULOJIX in both the U.S. and Europe, and ELIQUIS in Europe for the prevention of venous thromboembolic events. Business development remained a top priority as the Company executed twelve strategic transactions in 2011, and announced the planned acquisition of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 Pfizer Inc. and Bristol-Myers Squibb Co. s blood-thinner apixaban won a final recommendation from the U.K. s health-cost agency. The pill, also known by the brand name Eliquis, may be used to prevent blood clots in adults who have undergone hip or knee replacement surgery, the National Institute for Health and Clinical Excellence said in a statement today. The agency, known as NICE, advises the state-run National Health Service on which treatments represent value for money. Almost 120,000 hip (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 NEW YORK-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) today announced that its Board of Directors has elected Gerald L. Storch to the Board, effective yesterday. Mr. Storch will serve as a member of the Audit Committee, and the Compensation and Management Development Committee of the Board of Directors. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=98 United States Patent: 8101778 |-| Title: Five-membered heterocycles useful as serine protease inhibitors |-| Inventors: Hangeland; Jon J. (Morrisville, PA), Quan; Mimi L. (Yardley, PA), Smallheer; Joanne M. (Yardley, PA), Bisacchi; Gregory S. (Newtown Highlands, MA), Corte; James R. (Lawrenceville, NJ), Friends; Todd J. (Bordentown, NJ), Sun; Zhong (Hopewell, NJ), Rossi; Karen A. (Newtown, PA), Cavallaro; Cullen L. (Robbinsville, NJ) |-| Assignee: Bristol-Myers Squibb Company (Princeton, NJ) (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 They forgot to take the monkey out of the cage. Bristol-Myers Squibb accidentally killed a crab-eating macaque this past summer when its cage was run through the wash cycle while the primate remained locked inside, according to an inspection report from the U.S. Department of Agriculture. A spokeswoman for Bristol-Myers confirmed the accident but did not know how it occurred or the monkey s gender. The monkey died on July 1 at Bristol-Myers lab in Pennington, the inspection report said. The (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 PRINCETON, N.J. & WILMINGTON, Del.-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for investigational compound dapagliflozin for the treatment of type 2 diabetes in adults. The complete response letter requests additional clinical data to allow a better assessment of the benefit-risk profile for dapagliflozin. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 PRINCETON, N.J.-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) today announced a donation of $6.9 million in 2011 to support the HealthWell Foundation, an independent non-profit organization that provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments. The donation was made to HealthWell s co-pay assistance funds to help underinsured cancer patients with their out-of-pocket disease related (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Atrial fibrillation (AF) is the most common arrhythmia encountered by generalists and cardiologists alike. Much of the attendant morbidity from AF arises from systemic embolic complications which are effectively reduced with utilization of anti-platelet and/or anticoagulant therapy. The systemic embolic complications of AF and the medical therapy to attenuate these risks are very well established. Through the course of this review, we aim to highlight the complex relationship between AF and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 Second City Communications and Corpedia Release Funny and Engaging Video Called œCompany Retreating  Exploring Boundaries and Privacy When Using Social Media At The Office œCompany Retreating  is One of Many Timely, Relevant Videos on Ethics and Compliance Topics Served Up In the Innovative Video Library Called RealBiz Shorts CHICAGO-(BUSINESS WIRE)- Just because the boss can connect with employees through online social networks, is it a good idea? And if managers do connect to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Renal allograft survival is related directly to cell senescence. In the transplantation scenario many cellular events - participating as immunological and non-immunological factors - could contribute to accelerate this biological process, responsible for the ultimate fate of the graft. Mechanisms concerned in tolerance versus rejection are paramount in this outcome. For this reason, immunosuppressive treatment constitutes an extremely important decision to prevent organ dysfunction and, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 The U.K.'s health-cost regulator Friday backed Novartis AG's (NOVN.VX) cancer drug Tasigna for first-line treatment of chronic myeloid leukemia after the Swiss drug maker offered a discount, but Bristol-Myers Squibb Co.'s (BMY) rival product Sprycel was rejected. The decision from the National Institute for Health and Clinical Excellent, or NICE, confirmed a draft guidance published in December. NICE, which decides which treatments should be used in the U.K.'s publicly funded National Health (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 The influence of naturally occurring polymorphisms on the potency of the HCV NS5A replication complex inhibitor BMS-790052 was investigated by evaluating hybrid replicons in which the entire NS5A coding region of genotype (GT) la and 1b laboratory (lab) strains (H77c and Con1) were replaced with the corresponding regions of specimens collected from ten GT-1a and six GT-1b infected subjects. For baseline (BL) specimens, with no previously observed resistance variants indentified by population (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Foam granulation is a relatively newer wet granulation process whereby foamed binder solutions are added to powders in a mixer. It is essential to understand the effect of powder substrate on foam drainage and half-life, which are relevant to nucleation and agglomeration during foam granulation. Hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC) foams were characterized. Anhydrous lactose and stearic acid were selected as model soluble and insoluble substrates, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 AIMS/HYPOTHESIS: A positive impact of exercise intervention programmes on quality of life (QoL) may be important for long-term patient compliance to exercise recommendations. We have previously shown that QoL improves significantly with supervised exercise, whereas it worsens with counselling alone, in patients with type 2 diabetes from the Italian Diabetes and Exercise Study (IDES). Here, we report data on the relationship between changes in QoL and volume of physical (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 NEW YORK-(BUSINESS WIRE)-Levi & Korsinsky is investigating the Board of Directors of Inhibitex, Inc. ( œInhibitex  or the œCompany ) (Nasdaq: INHX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Bristol-Myers Squibb Co. (NYSE: BMY). Under the terms of the transaction, Inhibitex shareholders will receive $26 per share of Inhibitex stock they own. The transaction has a total approximate value of $2.5 billion. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 Merck & Co. (MRK) will consider making acquisitions as part of its strategy to develop the next generation of hepatitis C treatments, the drug maker's research chief said Tuesday. The search for better hepatitis C drugs has produced some eye-popping deals in the drug industry recently, including Gilead Sciences Inc. (GILD) planned $11 billion purchase of Pharmasset Inc. (VRUS) and Bristol-Myers Squibb Co.'s (BMY) agreement to acquire Inhibitex Inc. (INHX) for $2.5 billion. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 Cypress, California and San Francisco January 10, 2012 West Coast Clinical Trials, LLC (WCCT), a contract research organization (CRO) supporting early phase biopharmaceutical and device development, today announced it has received a substantial equity investment from Housatonic Partners, a $1 billion San Francisco-based private equity firm with expertise in the healthcare and pharmaceutical services markets. Terms of the investment were not disclosed. WCCT Global specializes in complex Phase (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 We report the synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamides (4) as CCR2 inhibitors for the potential treatment of inflammatory diseases. Several of the compounds display nanomolar binding affinity for CCR2. The in vitro structure-activity relationships of 4 are described, and are also reconciled with those from the related 2-phenylsulfonylmethyl series. |-| Bioorg Med Chem Lett. |-| Yang MG, Xiao Z, Shi Q, Cherney RJ, Tebben AJ, De Lucca GV, Santella JB, Mo R, Cvijic ME, Zhao (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 : Determine the prevalence and costs of rheumatoid arthritis (RA) during three consecutive years: 2004, 2005, and 2006. |-| J Occup Environ Med. |-| Simons WR, Rosenblatt LC, Trivedi DN. |-| From the Global Health Economics and Outcomes Research Inc (Dr Simons), Summit, NJ; and Health Economics and Outcomes Research (Drs Rosenblatt and Trivedi), Bristol-Myers Squibb, Princeton, NJ, E-mail: rsimons@globalhealtheconomics.com. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 PEGylation is the covalent attachment of polyethylene glycol to proteins, and it can be used to alter immunogenicity, circulating half life and other properties of therapeutic proteins. To determine the impact of PEGylation on protein conformation, we applied hydrogen/deuterium exchange mass spectrometry (HDX MS) to analyze granulocyte colony stimulating factor (G-CSF) upon PEGylation as a model system. The combined use of HDX automation technology and data analysis software allowed (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 Nowadays, many cytotoxic anticancer drugs exhibit low solubility and poor tumor selectivity, which means that the drug formulation is very important. For example, in the case of paclitaxel (PTX), Cremophor EL() (BASF, Ludwigshafen, Germany) needs to be used as a solubilizer in its clinical formulation (Taxol(), Bristol-Myers Squibb, New York, NY), although it can cause serious side effects. Nanomicellar systems are promising carriers to resolve the above problems, and the polymer chosen is (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 January 10, 2012 - Norwich Pharmaceuticals today announced that Terence Novak has joined the company as president, Commercial Operations. Novak will provide strategic leadership for Norwich Pharmaceuticals' commercial business group that includes sales, marketing and customer service. Novak will report to Chief Executive Officer Doug Drysdale. "We are pleased to welcome Terry Novak to Norwich and look forward to his results-oriented approach to business development and customer service," (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=98 United States Patent: 8093243 |-| Title: Hepatitis C virus inhibitors |-| Inventors: Bachand; Carol (Candiac, CA), Belema; Makonen (North Haven, CT), Deon; Daniel H. (Brossard, CA), Good; Andrew C. (Wallingford, CT), Goodrich; Jason (Meriden, CT), James; Clint A. (Longueuil, CA), Lavoie; Rico (Candiac, CA), Lopez; Omar D. (Wallingford, CT), Martel; Alain (Delson, CA), Meanwell; Nicholas A. (East Hampton, CT), Nguyen; Van N. (Meriden, CT), Romine; Jeffrey Lee (Meriden, CT), Ruediger; Edward H. (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=98 United States Patent: 8093276 |-| Title: Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |-| Inventors: Starrett, Jr.; John E. (Middletown, CT), Gillman; Kevin W. (Madison, CT), Olson; Richard E. (Orange, CT) |-| Assignee: Bristol-Myers Squibb Company (Princeton, NJ) |-| The present invention provides a method for the treatment of head trauma, traumatic brain injury, and/or dementia pugilistica comprising administering a therapeutically effective (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=98 United States Patent: 8093257 |-| Title: [6,5]-bicyclic GPR119 G protein-coupled receptor agonists |-| Inventors: Fevig; John M. (Doylestown, PA), Wacker; Dean A. (Yardley, PA) |-| Assignee: Bristol-Myers Squibb Company (Princeton, NJ) |-| Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 CHICAGO, Illinois, January 9, 2012 - Only 10% of molecules that enter Phase II will reach market, according to recent analysis by the Pharmaceutical Benchmarking Forum (PBF). And that is on top of growing attrition rates in earlier phases for preclinical and initial human studies that make the overall challenge of bringing drugs through Development even greater. This analysis is based on very detailed data from the PBF - which consists of the leading pharmaceutical companies - and offers the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 NEW YORK-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter and full year of 2011 on Thursday, January 26, 2012. During a conference call at 10:30 a.m. EST on January 26, company executives will review financial information and will address inquiries from investors and analysts. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=98 Amgen Inc. and Celgene Corp. may dive into deal-making this year as the biggest biotechnology companies seek to return to the industry s high-growth roots. Amgen and Celgene are trying to boost investor returns that have lagged behind peers and may have to compete with traditional acquirers from the pharmaceutical industry, such as New York-based Pfizer Inc. and Bristol-Myers Squibb Co. In the past five years, the Nasdaq Biotechnology Index has increased 36 percent while Amgen, the world s (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=98 BMS-790052, a first-in-class Hepatitis C Virus (HCV) replication complex inhibitor, targeting nonstructural protein 5A (NS5A), displays picomolar to nanomolar potency against genotypes 1-5. This exceptional potency translated into robust anti-HCV activity in clinical studies with HCV genotype 1-infected subjects. To date, all BMS-790052-associated resistance mutations have mapped to the N-terminal region of NS5A. To further characterize the antiviral activity of BMS-790052, HCV replicon (…)